Is Curative Biotechnology Stock a Good Investment?
Curative Biotechnology Investment Advice | CUBT |
- Examine Curative Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Curative Biotechnology's leadership team and their track record. Good management can help Curative Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Curative Biotechnology's business and its evolving consumer preferences.
- Compare Curative Biotechnology's performance and market position to its competitors. Analyze how Curative Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Curative Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Curative Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Curative Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Curative Biotechnology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Curative Biotechnology Stock
Researching Curative Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.01. Curative Biotechnology had not issued any dividends in recent years. The entity had 1:400 split on the 2nd of December 2022.
To determine if Curative Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Curative Biotechnology's research are outlined below:
| Curative Biotechnology had very high historical volatility over the last 90 days | |
| Curative Biotechnology has some characteristics of a very speculative penny stock | |
| Curative Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Curative Biotechnology currently holds 1.37 M in liabilities with Debt to Equity (D/E) ratio of 6.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Curative Biotechnology has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Curative Biotechnology's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 132.32 K. Net Loss for the year was (3.56 M) with profit before overhead, payroll, taxes, and interest of 100.21 K. | |
| Curative Biotechnology currently holds about 126.85 K in cash with (1.02 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize |
Curative Biotechnology Quarterly Liabilities And Stockholders Equity |
|
Curative Biotechnology's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.77 M.Market Cap |
|
Curative Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.37) | (4.16) | |
| Return On Capital Employed | 0.50 | 0.52 | |
| Return On Assets | (1.65) | (1.57) | |
| Return On Equity | 0.73 | 0.76 |
Determining Curative Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Curative Biotechnology is a good buy. For example, gross profit margin measures Curative Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Curative Biotechnology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Curative Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Curative Biotechnology. Check Curative Biotechnology's Beneish M Score to see the likelihood of Curative Biotechnology's management manipulating its earnings.
Evaluate Curative Biotechnology's management efficiency
Curative Biotechnology has return on total asset (ROA) of (0.6402) % which means that it has lost $0.6402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9828) %, meaning that it created substantial loss on money invested by shareholders. Curative Biotechnology's management efficiency ratios could be used to measure how well Curative Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Curative Biotechnology's Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 0.76 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (4.16). At this time, Curative Biotechnology's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.9 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.01) | (0.01) | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (5.52) | (5.80) | |
| Price Book Value Ratio | (2.37) | (2.48) | |
| Enterprise Value Multiple | (5.52) | (5.80) | |
| Price Fair Value | (2.37) | (2.48) | |
| Enterprise Value | 13 M | 6.8 M |
Curative Biotechnology's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.371 |
Basic technical analysis of Curative Stock
As of the 22nd of July, Curative Biotechnology shows the Standard Deviation of 10.57, mean deviation of 7.59, and Risk Adjusted Performance of 0.0067. Curative Biotechnology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Curative Biotechnology's Outstanding Corporate Bonds
Curative Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Curative Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Curative bonds can be classified according to their maturity, which is the date when Curative Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Curative Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Curative Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0067 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 7.59 | |||
| Coefficient Of Variation | (39,302) | |||
| Standard Deviation | 10.57 | |||
| Variance | 111.62 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 45.07 | |||
| Value At Risk | (19.39) | |||
| Potential Upside | 20.56 | |||
| Skewness | 0.3387 | |||
| Kurtosis | 0.6423 |
| Risk Adjusted Performance | 0.0067 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 7.59 | |||
| Coefficient Of Variation | (39,302) | |||
| Standard Deviation | 10.57 | |||
| Variance | 111.62 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (1.58) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 45.07 | |||
| Value At Risk | (19.39) | |||
| Potential Upside | 20.56 | |||
| Skewness | 0.3387 | |||
| Kurtosis | 0.6423 |
Consider Curative Biotechnology's intraday indicators
Curative Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Curative Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Curative Biotechnology time-series forecasting models is one of many Curative Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Curative Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Curative Stock media impact
There is far too much social signal, news, headlines, and media speculation about Curative Biotechnology that are available to investors today. This information is accessible both publicly - through Curative Biotechnology's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Curative-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Curative Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Curative Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Curative Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Curative Biotechnology alpha.
Curative Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Curative Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Curative Biotechnology Corporate Management
| BS BA | Vice Officer | Profile | |
| Pam Bisikirski | Vice Communications | Profile | |
| JD Esq | CFO, CEO | Profile | |
| Ronald Bordens | Executive Board | Profile |
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.